

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 9/127	A1	(11) International Publication Number: WO 93/15719 (43) International Publication Date: 19 August 1993 (19.08.93)
<p>(21) International Application Number: PCT/EP93/00273</p> <p>(22) International Filing Date: 4 February 1993 (04.02.93)</p> <p>(30) Priority data: 92200397.5 12 February 1992 (12.02.92) EP (34) Countries for which the regional or international application was filed: DE et al.</p> <p>(71) Applicant (for all designated States except US): JANSSEN FARMACEUTICI S.P.A. [IT/IT]; Viale Castello della Magliana, 38, I-00148 Rome (IT).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): LUCCHETTI, Giovanni [IT/IT]; Via Mengoni, 7, I-00128 Rome (IT). ASSOGNA, Giuseppe [IT/IT]; Via Cechov, 107, I-00142 Rome (IT). BAGNATO, Pietro [IT/IT]; Via Teano, 33, I-04100 Latina (IT).</p>		<p>(74) Agent: WANTE, Dirk; Janssen Pharmaceutica N.V., Patent Department, Turnhoutseweg 30, B-2340 Beerse (BE).</p> <p>(81) Designated States: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, NZ, PL, PT, RO, RU, SD, SK, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).</p> <p>Published With international search report.</p>
<p>(54) Title: LIPOSOMAL ITRACONAZOLE FORMULATIONS</p> <p>(57) Abstract</p> <p>The present invention relates to a topical liposomal formulation comprising itraconazole, a phospholipid, a solvent system for itraconazole and said phospholipid, water and conventional auxiliary formulating agents, and a method of preparing said formulation.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TO	Togo
CZ	Czech Republic	MC	Madagascar	TG	Togo
DE	Germany	ML	Mali	UA	Ukraine
DK	Denmark	MN	Mongolia	US	United States of America
ES	Spain			VN	Viet Nam
FI	Finland				

5

Liposomal itraconazole formulations

10 The present invention relates to a topical liposomal formulation comprising itraconazole, a phospholipid, a solvent system for itraconazole and said phospholipid, water and conventional auxiliary formulating agents, and a method of preparing said formulation.

WO 8903-679-A discloses classic liposome compositions comprising antimycotic agents;
15 similarly JP-2204-413-A discloses classic liposome compositions with fungicides as active ingredient such as antimycotic agents.

EP-0,253,619 describes a convenient method for preparing single bilayered liposomes containing encapsulated active ingredients such as antimycotic agents.

20 Itraconazole is an antifungal drug which is sparingly soluble in aqueous and/or alcoholic media. This property has hitherto effectively precluded the development of efficacious topical itraconazole formulations. This problem has now been solved by using an especially designed organic solvent system.

25 The present liposomal itraconazole formulation penetrates rapidly and deeply in epithelial tissues and shows excellent retention of the active ingredient therein. The efficacy of the composition for treating topical fungal infections is superb. The present formulation is stable and in particular does not show the disadvantage of crystallization of the sparingly soluble active ingredient itraconazole.

30

The present invention provides a topical liposomal formulation comprising itraconazole, a phospholipid, a solvent system for itraconazole and said phospholipid, water and conventional auxiliary formulating agents, characterized in that said composition comprises as a solvent system dimethylisosorbide and tetraglycol. Both the liposomal
35 formulations of itraconazole and the use of said solvent system in topical liposomal formulations is novel.

The present composition is preferably in the form of single bilayered liposomes, in particular liposomes having a size ranging from 100 to 1000 nm, more in particular from

100 to 500 nm. In general, the stability of the liposomal formulation increases as the size of the single bilayered liposomes decreases. Single bilayered liposomes, also referred to as unilamellar vesicles, consist of a single bilayer of suitable amphophilic molecules such as phospholipids which encapsulate an aqueous phase and which are separated from each other by an aqueous phase.

Hereinafter, the amounts of each of the ingredients in the present composition are expressed as percentages by weight based on the total weight of the formulation. Similarly, ratios are intended to define weight-by-weight ratios.

Suitable phospholipids for use in the present composition are, for example, phosphatidyl cholines, ethanolamines and serines, sphingomyelins, cardiolipins, plasmalogens, phosphatidic acids and cerebrosides, in particular those which are soluble together with itraconazole in non-toxic, pharmaceutically acceptable organic solvents. Preferred phospholipids are, for example, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl inositol, lysophosphatidyl choline, phosphatidyl glycerol and the like, and mixtures thereof especially lecithin, e.g. soya lecithin. The amount of phospholipid used in the present formulation can range from about 10 to about 30%, preferably from about 15 to about 25% and in particular is about 20%.

Lipophilic additives may be employed advantageously to modify selectively the characteristics of the liposomes. Examples of such additives include, for example, stearylamine, phosphatidic acid, tocopherol, cholesterol, cholesterol hemisuccinate and lanolin extracts; cholesterol being a lipophilic additive of choice. The amount of lipophilic additive used can range from 0.5 to 8%, preferably from 1.5 to 4% and in particular is about 2%. Generally, the ratio of the amount of lipophilic additive to the amount of phospholipid ranges from about 1:8 to about 1:12 and in particular is about 1:10.

Said phospholipid, lipophilic additive and the active ingredient itraconazole are employed in conjunction with a non-toxic, pharmaceutically acceptable organic solvent system which can dissolve said ingredients. The organic solvent system used in the present formulation is of crucial importance. Said solvent system not only must dissolve the active ingredient itraconazole completely, but it also has to allow the formulation of stable single bilayered liposomes. The solvent system comprises dimethylisorbide and tetraglycol (glycofurol, tetrahydrofurfuryl alcohol polyethylene glycol ether) in an amount of about 8 to about 30%, in particular about 12 to about 20% and preferably about 15%. In said solvent system, the ratio of the amount of dimethylisorbide to the

amount of tetraglycol can range from about 2:1 to about 1:3, in particular from about 1:1 to about 1:2.5 and preferably is about 1:2. The amount of tetraglycol in the final composition thus can vary from 5 to 20%, in particular from 5 to 15% and preferably is approximately 10%. The amount of dimethylisosorbide in the final composition thus can range from 3 to 10%, in particular from 3 to 7% and preferably is approximately 5%.

The term "organic component" as used hereinafter refers to mixtures comprising said phospholipid, lipophilic additives and organic solvents.

The active ingredient itraconazole is dissolved in the organic component. It may be advantageous to use micronized forms of the active ingredient to facilitate its dissolution. The amount of active ingredient in the final formulation ranges from 0.1 to 0.6%, in particular from 0.4 to 0.5% and preferably is approximately 0.5%. In addition, other ingredients such as anti-oxidants may be added to the organic component. Examples thereof include tocopherol, butylated hydroxyanisole, butylated hydroxytoluene, ascorbyl palmitate, ascorbyl oleate and the like.

The aqueous component of the present formulation comprises mainly water and may contain various additives such as electrolytes, buffer systems, preservatives and the like. Suitable electrolytes include metal salts, in particular alkali metal and earth alkaline metal salts such as, for example, calcium chlorides, sodium chloride, potassium chloride, preferably sodium chloride. The concentration of the electrolytes may vary over a wide range and depends on the nature and the concentration of each of the ingredients in the final formulation and should be sufficient to stabilize the liposomal membranes. In the present composition the amount of sodium chloride can range from 0.05 to 0.2% and in particular is about 0.1%. Buffer systems comprise mixtures of appropriate amounts of an acid such as phosphoric, succinic, or preferably citric acid, and a base, in particular sodium hydroxide. Said buffer systems should maintain the pH of the formulation within the range of 5 to 7, preferably within the range of 5 to 6.5 and especially within the range of 5.5 to 6. Preservatives which can be employed in the present composition to prevent degradation by microorganisms comprise benzoic acid, methylparaben and propylparaben. Preferably, methylparaben and propylparaben are used in an amount of approximately 0.2 % and 0.02 % respectively. It is especially advantageous to add to the aqueous component a chelating agent such as sodium or disodium edetate in order to prevent the oxidative degradation of the phospholipid in the final formulation by metal ions. An effective amount of for example disodium edetate ranges from 0.05 % to 0.25 % and in particular is approximately 0.15 %.

Preferred compositions comprise by weight based on the total weight of the composition :

- (a) 0.1 to 0.6% itraconazole;
- (b) 10 to 30% phospholipid;
- 5 (c) 0.5 to 8% cholesterol;
- (d) 3 to 10% dimethylisosorbide;
- (e) 5 to 20% tetraglycol;
- (f) buffer to maintain the pH of the composition within the range of 5 to 7;
- (g) sufficient electrolytes to stabilize the liposomal membranes;
- 10 (h) sufficient dermatologically acceptable preservatives to prevent degradation of the composition;
- (i) 0.5 to 1.5% thickening agent; and
- (j) water.

15 Particularly preferred compositions are those wherein :

- the amount of itraconazole is 0.4 to 0.5%;
- the amount of phospholipid is 15 to 25%;
- the amount of cholesterol is 1.5% to 4%;
- the amount of dimethylisosorbide is 3 to 7%;
- 20 the amount of tetraglycol is 5 to 15%; and
- the amount of thickening agent is 1%.

The most preferred composition comprises approximately :

- (a) 0.5% itraconazole;
- 25 (b) 20% phospholipid;
- (c) 2% cholesterol;
- (d) 5% dimethylisosorbide;
- (e) 10% tetraglycol;
- (f) 0.06% sodium hydroxide and 0.1% citric acid;
- 30 (g) 0.1% sodium chloride;
- (h) 0.2% methylparaben, 0.02% propylparaben, 0.01% butylated hydroxytoluene, and 0.15% disodium edetate;
- (i) 1% hydroxypropyl methylcellulose; and
- (j) water.

35

The liposomal itraconazole formulation of the present invention can preferably be prepared by (a) heating the phospholipid and the organic solvent system to about 60 to 80°C, preferably to about 70 to 75°C in a first vessel, dissolving the active ingredient

therein, adding thereto the auxiliary formulating agents, and stirring the mixture until complete dissolution is obtained ;

- 5 (b) heating part of the water to 90 - 95°C in a second vessel and dissolving the preservatives therein, allowing the mixture to cool and then adding the remainder of the auxiliary formulating agents and the remainder of the water, and stirring the mixture until complete dissolution is obtained ; thus preparing the aqueous component ;
- (c) transferring the contents of the first vessel by means of a vacuum directly into the aqueous component, while homogenizing the thus obtained combination with a high performance mixing apparatus, in particular a high-shear mixer ; and
- 10 (d) adding a thickener to the resulting mixture by means of a vacuum while further homogenizing.

- Preferably, the aqueous component is placed in a suitable vessel which can be equipped with a homogenizer and homogenization is effected by creating great turbulence during the injection of the organic component. Any mixing means or homogenizer which exerts
- 15 high shear forces on the mixture may be employed. Generally, a mixer capable of speeds from about 1,500 to 20,000 rpm, in particular from about 3,000 to about 6,000 rpm may be employed. Suitable thickening agents for use in process step (d) are for example, xanthan gum, hydroxypropyl cellulose, hydroxypropyl methylcellulose or mixtures thereof, cellulose derivatives being preferred. The amount of thickening agent depends
- 20 on the nature and the concentration of the other ingredients and in general ranges from about 0.5 to 1.5%, and in particular is approximately 1%.

- In order to prevent degradation of the materials used during the preparation of the liposomal formulation, it is advantageous to purge all solutions with an inert gas such as
- 25 nitrogen or argon, and to conduct all steps under an inert atmosphere.

- Liposomes prepared by the above described method usually contain most of the active ingredient bound in the lipid bilayer and separation of the liposomes from unencapsulated
- 30 material is not required. The single bilayered liposomes can conveniently be employed directly or they may also be employed in combination with other suitable pharmaceutically acceptable carriers for topical administration.

- The above described liposomal compositions are particularly useful for the topical treatment of subjects suffering from topical fungal infections, in particular for treating
- 35 acute forms of said problems. The itraconazole containing compositions are applied topically to the area to be treated at regular intervals, as needed, generally once, twice or

thrice a day. The duration of the treatment will depend on the nature, extent and severity of the condition to be treated as well as the frequency of applying the composition.

The following examples are intended to illustrate the scope of the present invention in all its aspects and not to limit it thereto.

Example 1

Ingredient	Quantity, mg/g of cream
itraconazole	5.0
soya lecithin	200.0
cholesterol	20.0
tetraglycol	100.0
dimethylisosorbide	50.0
methylparaben	2.0
propylparaben	0.2
butylated hydroxytoluene	0.1
disodium edetate	1.5
sodium chloride	1.0
hydroxypropyl methylcellulose	10.0
sodium hydroxide	0.6
citric acid	1.0
purified water, USP	608.6

Procedure

- 10 1. Heat the soya lecithin, tetraglycol and dimethyl isosorbide to about 70-75°C.
Dissolve the itraconazole, cholesterol and butylated hydroxytoluene in the heated mixture. Stir until complete dissolution is obtained.
- 15 2. Heat about one third of the water to 80-95°C in a separate vessel and dissolve the preservatives methylparaben and propylparaben in the heated water while stirring.
Allow the solution to cool to about 25°C and then add the disodium edetate, sodium chloride, sodium hydroxide and citric acid. Add the remainder of the water and stir to obtain a complete solution.
- 20 3. Transfer the mixture resulting from step 1 into the mixture resulting from step 2 by means of a vacuum, while homogenizing the combination with a high-shear mixer until a homogeneous product is obtained.

4. Add the hydroxypropyl methylcellulose into the mixture resulting from step 3 by means of a vacuum while homogenizing with a mixer.

5 The homogenizer was a Silverson high-shear mixer operating at approximately 3000 rpm. The flow rate during the transfer steps was about 0.5 l/min. Single bilayered liposomes were formed. The white lipogel cream resulting from step 4 can conveniently be filled in suitable containers such as tubes, e.g. PVC-covered aluminum tubes.

Claims

1. A topical liposomal composition comprising itraconazole, a phospholipid, a solvent system for itraconazole and said phospholipid, water and conventional auxiliary
5 formulating agents, characterized in that said composition comprises as a solvent system dimethylisorbide and tetraglycol.
2. A composition according to claim 1 wherein the liposomes are single bilayered
10 liposomes.
3. A composition according to claim 2 wherein the phospholipid is lecithin.
4. A composition according to claim 3 wherein the amount of dimethylisorbide and
15 tetraglycol ranges from 8 to 30% by weight based on the total weight of the composition.
5. A composition according to claim 4 wherein the ratio of the amount of
dimethylisorbide to the amount of tetraglycol ranges from 2:1 to 1:3.
6. A composition according to claim 1 comprising by weight based on the total weight
20 of the composition :
 - (a) 0.1 to 0.6% itraconazole;
 - (b) 10 to 30% phospholipid;
 - (c) 0.5 to 8% cholesterol;
 - (d) 3 to 10% dimethylisorbide;
 - 25 (e) 5 to 20% tetraglycol;
 - (f) buffer to maintain the pH of the composition within the range of 5 to 7;
 - (g) sufficient electrolytes to stabilize the liposomal membranes;
 - (h) sufficient dermatologically acceptable preservatives to prevent degradation of the
composition;
 - 30 (i) 0.5 to 1.5% thickening agent; and
 - (j) water.
7. A composition according to claim 6 wherein
35 the amount of itraconazole is 0.4 to 0.5%;
the amount of phospholipid is 15 to 25%;
the amount of cholesterol is 1.5% to 4%;
the amount of dimethylisorbide is 3 to 7%;
the amount of tetraglycol is 5 to 15%; and
the amount of thickening agent is 1%.

8. A composition according to claim 7 comprising approximately;
- (a) 0.5% itraconazole;
 - (b) 20% phospholipid;
 - 5 (c) 2% cholesterol;
 - (d) 5% dimethylisobutylate;
 - (e) 10% tetraglycol;
 - (f) 0.06% sodium hydroxide and 0.1% citric acid;
 - (g) 0.1% sodium chloride;
 - 10 (h) 0.2% methylparaben, 0.02% propylparaben, 0.01% butylated hydroxytoluene, and 0.15% disodium edetate;
 - (i) 1% hydroxypropyl methylcellulose; and
 - (j) water.
- 15 9. A process for preparing a composition as claimed in any one of claims 1 to 8 characterized in that said process comprises the steps of :
- (a) heating the phospholipid and the organic solvent system in a first vessel, dissolving the active ingredient therein, adding thereto the auxiliary formulating agents, and stirring until complete dissolution is obtained;
 - 20 (b) heating part of the water in a second vessel, dissolving the preservatives therein, allowing the mixture to cool and then adding the remainder of the auxiliary formulating agents and the remainder of the water, and stirring until complete dissolution is obtained, thus preparing the aqueous component;
 - (c) transferring the contents of the first vessel by means of a vacuum directly into the
 - 25 (d) adding a thickener to the resulting mixture by means of a vacuum while further homogenizing.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 93/00273

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 A61K9/127		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	A61K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	EP,A,0 230 226 (KALI-CHEMIE PHARMA) 29 July 1987 see claim 1 ---	1-9
A	EP,A,0 215 423 (DOLORGIET) 25 March 1987 see claim 10 ---	1-9
A	EP,A,0 427 582 (CROOKS M.J.) 15 May 1991 see abstract ---	1-9
A	WO,A,8 807 871 (WARNER-LAMBERT) 20 October 1988 see page 2, line 23 ---	1-9
	-/--	
¹⁰ Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) of which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
10 MARCH 1993	01.04.93	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	AVEDIKIAN P.F.	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	WO,A,8 903 679 (THE LIPOSOME COMPANY) 5 May 1989 cited in the application see page 7, line 23 - line 27 -----	1-9
A	EP,A,0 253 619 (CILAG) 20 January 1988 cited in the application see column 4, line 56 - line 59 -----	1-9

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

EP 9300273
SA 69644

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

10/03/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0230226	29-07-87	DE-A- 3600947	16-07-87
		DE-A- 3771881	12-09-91
EP-A-0215423	25-03-87	DE-A- 3532562	12-03-87
		CA-A- 1269328	22-05-90
		JP-A- 62061917	18-03-87
		US-A- 4849418	18-07-89
EP-A-0427582	15-05-91	AU-B- 628671	17-09-92
		US-A- 5169846	08-12-92
WO-A-8807871	20-10-88	US-A- 4783450	08-11-88
		EP-A- 0382716	22-08-90
		JP-T- 2502994	20-09-90
WO-A-8903679	05-05-89	EP-A- 0382777	22-08-90
		JP-T- 3500652	14-02-91
EP-A-0253619	20-01-88	AU-B- 598002	14-06-90
		AU-A- 7538587	21-01-88
		DE-A- 3776015	27-02-92
		JP-A- 63116737	21-05-88

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.